Robeco Institutional Asset Management B.V. Trims Stock Holdings in Illumina, Inc. $ILMN

FierceBiotechRare Disease Research, myTomorrows team up to help patients access trials

FierceBiotechAligos sells China rights to HBV drug to hepatology player Amoytop in $445M deal

FierceBiotechPfizer–backed Storm blows into $56M series C, launches phase 2 sarcoma trial

FierceBiotechJohnson & Johnson hands back failed eye disease gene therapy to MeiraGTx

FierceBiotech'Absent or trivial' effects: Anti-amyloid Alzheimer's drugs called into question once again

Thermo FisherThermo Fisher Scientific (TMO) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Promega BlogStolen Chloroplasts and the Chrysalis of Complex Life

IlluminaDRAGEN v4.5 supports Illumina's new TruPath Genome and 5-base assays, drives insights across germline, oncology, and multiomic workflows - PR Newswire

Lonza NewsKeyBanc reiterates Lonza stock rating on strong modality positioning By Investing.com - Investing.com Canada

BioWorldPerha Pharmaceuticals identifies new adenosine A3 receptor antagonists

BioWorldCogent Biosciences identifies new JAK2 V617F inhibitors

BioWorldCorbus Pharmaceuticals synthesizes new cannabinoid CB1 receptor antagonists or inverse agonists